Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
UBX | US
-0.04
-2.82%
Healthcare
Biotechnology
01/01/1970
17/10/2024
1.38
1.41
1.41
1.35
Unity Biotechnology Inc. a biotechnology company engages in the research and development of therapeutics to slow halt or reverse diseases of aging. The company's lead drug candidate includes UBX1325 which is phase II clinical trial for the treatment of age-related diseases of the eye including diabetic macular edema age-related macular degeneration and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050 a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089 a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge Inc. and changed its name to Unity Biotechnology Inc. in January 2015. Unity Biotechnology Inc. was incorporated in 2009 and is headquartered in South San Francisco California.
View LessNegative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Current Volume and Negative 1-Day Return
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
37.9%1 month
27.6%3 months
41.8%6 months
46.1%-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.19
Range1M
0.19
Range3M
0.39
Rel. volume
2.22
Price X volume
116.91K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Vanda Pharmaceuticals Inc | VNDA | Biotechnology | 4.735 | 0 | -3.37% | n/a | |
Viking Therapeutics Inc | VKTX | Biotechnology | 64.615 | 0 | -1.88% | n/a | |
VIRACTA THERAPEUTICS INC | VIRX | Biotechnology | 0.2228 | 0 | -0.45% | n/a | |
VINC | VINC | Biotechnology | 0.3775 | 0 | -5.15% | n/a | |
Vigil Neuroscience Inc. Common Stock | VIGL | Biotechnology | 3.99 | 0 | 3.37% | n/a | |
Verve Therapeutics Inc. Common Stock | VERV | Biotechnology | 5.46 | 0 | -2.50% | n/a | |
Vera Therapeutics Inc. Class A Common Stock | VERA | Biotechnology | 39.89 | 0 | -0.25% | n/a | |
Veracyte Inc | VCYT | Biotechnology | 34.31 | 0 | -1.18% | n/a | |
Vaccinex Inc - Ordinary Shares | VCNX | Biotechnology | 2.52 | 0 | -3.08% | n/a | |
Vericel Corporation | VCEL | Biotechnology | 40.67 | 0 | -1.45% | n/a |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a | |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.54 | 0 | -1.56% | n/a | |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | - | 0.53 | - |
Ent. to Revenue | - | 4,005.99 | - |
PE Ratio | - | 40.42 | - |
Price to Book | - | 15.30 | - |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 41.79 | 72.92 | Lower Risk |
Debt to Equity | - | -1.24 | - |
Debt to Assets | - | 0.25 | - |
Market Cap | - | 3.78B | - |